PASG Passage BIO, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.50M | $3.34M | $4.09M | $5.42M | $4.31M | $5.81M | $7.74M | $9.56M |
| SG&A expense | $3.44M | $6.87M | $4.79M | $4.92M | $4.35M | $4.52M | $6.08M | $4.71M |
| Operating income | -$4.94M | -$8.27M | -$8.25M | -$13.85M | -$8.65M | -$10.33M | -$16.46M | -$14.27M |
| Net income | -$4.72M | -$7.82M | -$7.56M | -$12.98M | -$7.75M | -$9.38M | -$15.40M | -$12.72M |
| EBITDA | -$4.94M | -$8.25M | -$8.12M | -$13.67M | -$8.46M | -$10.13M | -$16.26M | -$13.55M |
| EPS (basic) | -1.47 | -2.44 | -2.36 | — | -2.44 | -2.96 | -4.87 | — |
| EPS (diluted) | -1.47 | -2.44 | -2.36 | — | -2.44 | -2.96 | -4.87 | — |
| Weighted avg. shares (diluted) | 3.22M | 3.21M | 3.21M | — | 3.18M | 3.17M | 3.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.16M | $24.16M | $33.34M | $46.30M | $52.77M | $57.63M | $63.36M | $37.57M |
| Short-term investments | $0 | $0 | $0 | $0 | $0 | $0 | — | $39.18M |
| Current assets | $20.79M | $25.18M | $34.74M | $47.76M | $55.73M | $60.31M | $66.67M | $78.81M |
| PP&E, net | — | — | $826,000 | $4.11M | $5.16M | $5.34M | $5.52M | $9.33M |
| Total assets | $20.79M | $25.18M | $36.46M | $62.28M | $74.16M | $79.20M | $86.01M | $102.41M |
| Current liabilities | $20.74M | $20.72M | $20.10M | $23.08M | $22.25M | $19.80M | $17.82M | $19.36M |
| Total liabilities | $20.74M | $20.72M | $24.71M | $43.53M | $43.04M | $40.94M | $39.30M | $41.15M |
| Shareholders' equity | $50,000 | $4.46M | $11.75M | $18.75M | $31.12M | $38.26M | $46.71M | $61.26M |
| Shares outstanding | 3.22M | 3.22M | 3.21M | 3.18M | 3.18M | 3.18M | 62.15M | 3.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.00M | -$9.18M | -$12.99M | -$6.48M | -$4.85M | -$6.33M | -$13.85M | -$8.44M |
| Investing cash flow | $3,000 | $0 | $20,000 | $0 | $0 | $585,000 | $39.63M | $13.68M |
| Financing cash flow | — | — | — | $9,000 | $0 | — | — | $47,000 |
| Depreciation & amortization | $0 | $25,000 | $129,000 | $177,000 | $200,000 | $200,000 | $201,000 | $719,000 |
| Stock-based compensation | $313,000 | $525,000 | $556,000 | $609,000 | $611,000 | $923,000 | $858,000 | $1.25M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.